Goldman Sachs
HRMY icon

Goldman Sachs’s Harmony Biosciences HRMY Stock Holding History

Goldman Sachs’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.7M Sell
403,532
-835,675
-67% -$26.4M ﹤0.01% 2929
2026
Q1 		$34.7M Buy
1,239,207
+669,845
+118% +$22M ﹤0.01% 1894
2025
Q4 		$21.3M Sell
569,362
-77,291
-12% -$2.54M ﹤0.01% 2313
2025
Q3 		$17.8M Sell
646,653
-74,028
-10% -$2.55M ﹤0.01% 2372
2025
Q2 		$22.8M Buy
720,681
+375,915
+109% +$12.1M ﹤0.01% 2008
2025
Q1 		$11.4M Sell
344,766
-150,282
-30% -$5.39M ﹤0.01% 2563
2024
Q4 		$17M Buy
495,048
+187,035
+61% +$6.43M ﹤0.01% 2294
2024
Q3 		$12.3M Sell
308,013
-147,351
-32% -$5.18M ﹤0.01% 2510
2024
Q2 		$13.7M Buy
455,364
+244,410
+116% +$7.35M ﹤0.01% 2202
2024
Q1 		$7.08M Sell
210,954
-60,146
-22% -$1.93M ﹤0.01% 2790
2023
Q4 		$8.76M Buy
271,100
+69,142
+34% +$1.93M ﹤0.01% 2656
2023
Q3 		$6.62M Sell
201,958
-115,045
-36% -$3.99M ﹤0.01% 2746
2023
Q2 		$11.2M Sell
317,003
-11,331
-3% -$391K ﹤0.01% 2342
2023
Q1 		$10.7M Buy
328,334
+219,310
+201% +$9.99M ﹤0.01% 2356
2022
Q4 		$6.01M Sell
109,024
-56,587
-34% -$3.11M ﹤0.01% 3008
2022
Q3 		$7.33M Buy
165,611
+97,334
+143% +$4.75M ﹤0.01% 2799
2022
Q2 		$3.33M Buy
68,277
+4,618
+7% +$208K ﹤0.01% 3572
2022
Q1 		$3.1M Buy
63,659
+16,753
+36% +$683K ﹤0.01% 3828
2021
Q4 		$2M Sell
46,906
-7,610
-14% -$303K ﹤0.01% 4249
2021
Q3 		$2.09M Buy
54,516
+25,955
+91% +$836K ﹤0.01% 4164
2021
Q2 		$806K Buy
28,561
+14,741
+107% +$442K ﹤0.01% 4917
2021
Q1 		$457K Buy
13,820
+4,935
+56% +$173K ﹤0.01% 5192
2020
Q4 		$321K Sell
8,885
-29,178
-77% -$1.18M ﹤0.01% 4853
2020
Q3 		$1.29M Buy
+38,063
New +$1.39M ﹤0.01% 3897

Other funds holding HRMY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Goldman Sachs's HRMY Position: Q2 2026 in Review

Goldman Sachs reduced its Harmony Biosciences (HRMY) stake by 67% in Q2 2026, selling an estimated $26.4M and leaving 403,532 shares worth $14.7M. The position accounts for ﹤0.01% of the portfolio, ranked #2929.

Goldman Sachs first reported a position in HRMY in Q3 2020 and has held it in 24 quarters since. The position peaked at $34.7M in Q1 2026. 327 funds tracked by Wall St. Rank hold HRMY as of Q2 2026.

  • Goldman Sachs held 403,532 shares of Harmony Biosciences worth $14.7M as of Q2 2026.
  • Goldman Sachs sold 835,675 Harmony Biosciences shares in Q2 2026, an estimated $26.4M.
  • Harmony Biosciences made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #2929 holding.
  • Goldman Sachs first reported a position in Harmony Biosciences in Q3 2020 and has held it in 24 quarters since.
  • Goldman Sachs's Harmony Biosciences position peaked at $34.7M in Q1 2026.
  • 327 funds tracked by Wall St. Rank held Harmony Biosciences as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.